Zhejiang Conba Pharmaceutical Co., Ltd.
Zhejiang Kangenbei Pharmaceutical Co., Ltd. was formerly Lanxi Yunshan Pharmaceutical Factory. After more than 50 years of development, it has grown into a large-scale traditional Chinese medicine enterprise integrating drug research and development, production and sales. (SH600572) ). The company's controlling shareholder is Zhejiang Traditional Chinese Medicine Health Industry Group Co., Ltd. (a wholly-owned subsidiary of Zhejiang International Trade Group Co., Ltd.). The company is headquartered in Hangzhou, with Zhejiang as the industrial development center, and has established industrial bases in Jiangxi, Yunnan, Inner Mongolia and other provinces, with a total employee population of more than 8,000. The company has innovative platforms such as national innovative enterprises, national enterprise technology centers and postdoctoral research workstations, academician workstations, provincial key laboratory of traditional Chinese medicine and pharmaceutical technology, and provincial key enterprise research institutes. It has the following innovative platforms such as Kangenbe, Qianlikang, Tianbaoning and A big brand matrix represented by well-known brands such as Jindi and Jinaokang. Since it was officially included in the management system of the Provincial China Trade Group in July 2020, the company has taken "inheritance and integrity and innovation" as its fundamental guideline, focusing on core business, innovative development, and value improvement, laying a good foundation for building the main platform for traditional Chinese medicine and health industry in Zhejiang Province. . In the future, the company will focus on the development goals of the life and health industry of the Provincial Guomao Group, give full play to the advantages of the mixed reform system and mechanism, increase efforts to deepen the field of traditional Chinese medicine and health, and strive to make new breakthroughs in innovative platform construction, resource integration and development, and management quality improvement and efficiency improvement. , iterates its own competitiveness in the new development ecosystem, and becomes an important force in our province to build a highland for life, health, science and technology innovation, and contributes Kangenbei's strength to help the strong province of traditional Chinese medicine and high-quality development to build a demonstration zone for common prosperity.
Zhejiang Conba Pharmaceutical Co., Ltd.
Zhejiang Kangenbei Pharmaceutical Co., Ltd. was formerly Lanxi Yunshan Pharmaceutical Factory. After more than 50 years of development, it has grown into a large-scale traditional Chinese medicine enterprise integrating drug research and development, production and sales. (SH600572) ). The company's controlling shareholder is Zhejiang Traditional Chinese Medicine Health Industry Group Co., Ltd. (a wholly-owned subsidiary of Zhejiang International Trade Group Co., Ltd.). The company is headquartered in Hangzhou, with Zhejiang as the industrial development center, and has established industrial bases in Jiangxi, Yunnan, Inner Mongolia and other provinces, with a total employee population of more than 8,000. The company has innovative platforms such as national innovative enterprises, national enterprise technology centers and postdoctoral research workstations, academician workstations, provincial key laboratory of traditional Chinese medicine and pharmaceutical technology, and provincial key enterprise research institutes. It has the following innovative platforms such as Kangenbe, Qianlikang, Tianbaoning and A big brand matrix represented by well-known brands such as Jindi and Jinaokang. Since it was officially included in the management system of the Provincial China Trade Group in July 2020, the company has taken "inheritance and integrity and innovation" as its fundamental guideline, focusing on core business, innovative development, and value improvement, laying a good foundation for building the main platform for traditional Chinese medicine and health industry in Zhejiang Province. . In the future, the company will focus on the development goals of the life and health industry of the Provincial Guomao Group, give full play to the advantages of the mixed reform system and mechanism, increase efforts to deepen the field of traditional Chinese medicine and health, and strive to make new breakthroughs in innovative platform construction, resource integration and development, and management quality improvement and efficiency improvement. , iterates its own competitiveness in the new development ecosystem, and becomes an important force in our province to build a highland for life, health, science and technology innovation, and contributes Kangenbei's strength to help the strong province of traditional Chinese medicine and high-quality development to build a demonstration zone for common prosperity.
Shandong Hongjitang Pharmaceutical Group Co., Ltd.
The world's traditional Chinese medicine, the century-old Hongjitang. Shandong Hongjitang Pharmaceutical Group Co., Ltd. was founded in 1907 and has a history of more than 110 years. On the basis of inheriting the essence and adhering to the truth and innovation, it has established a modern Hongjitang Traditional Chinese Medicine Health City from a high starting point, completing the traditional manufacturing type to The leap of technology-leading has formed core competitiveness in many aspects. Hongjitang Pharmaceutical currently has 151 documents, and its products cover Chinese patent medicines, formula granules, Chinese herbal medicines, raw materials, donkey-hide gelatin and healthy foods. 35 products have entered the national basic medicine catalog and 90 products have entered the medical insurance catalog. There are 10 large dosage forms (pills, powders, tablets, mixtures, tinctures, gels, capsules, granules, decoctions, oral liquids), and 10 exclusive products (Qianlixin Capsules, Musk Heartburnin Tablets, Jinming Tablets , Compound Xiling Jiedu Capsules, Deer Bone Gum, Hailong Gecko Oral Liquid, Zhaqi Wan, Shuqi Wan, Jiawei Xiangsha Zhishu Wan, Musk Ketone). 10 products are listed as recommended medications for the diagnosis and treatment of new pneumonia (Huoxiang Zhengqi Water, Fangfeng Tongsheng Pills, Angong Niuhuang Pills, Suhexiang Pills, Comfang Xiling Jiedu Capsules/Pills, Lung Clearing and Detoxification Compound, Jinbei Oral Liquid, Qingwen Jiedu Pills, Qipi Pills). In terms of business model and network channels, Hongjitang OTC Pharmaceuticals directly supplies chain pharmacies, adopts the front-store and back-factory model to establish cooperation with more than 80% of the top 100 pharmaceutical chains in the country, and has cooperated with more than 100,000 pharmacies. Through cooperation with nationally renowned commercial companies such as China Resources, Jiuzhoutong, and Sinopharm Holdings, medical products have formed a sales network covering national-level hospitals and primary medical and health service centers, such as Qianlixin Capsules, Musk Heartburnin Tablets, Xuefu Zhuyu Oral Liquid, etc. The clinical efficacy of high-quality products is highly recognized by experts. Supermarket e-commerce channels directly sell the healthy food series to large domestic chain drug retailers, supermarkets, traditional Chinese medicine clinics and other terminals, and provide customers with products through online platforms such as JD.com and Tmall. Hongjitang Pharmaceutical has enhanced its core competitiveness through innovation, and has more than 10 scientific research and innovation platforms, including Shandong Traditional Chinese Medicine Technology Innovation Center for the Treatment of Respiratory Diseases, Traditional Chinese Medicine Development Strategy Research Center, Shandong Postdoctoral Innovation Practice Base, etc., and undertakes the country and province. Research on many major projects at the level. We cooperate closely with many academicians, national medical masters, and well-known scientific research institutes to hire many famous old Chinese medicine doctors to serve as honorary deans of the institute. On the one hand, we will carry out dosage form improvement, process improvement, clinical re-evaluation and other second rounds around the existing 151 document numbers. Development and research; on the other hand, focus on the advantages of traditional Chinese medicine, and carry out research in the directions of new traditional Chinese medicine, classic prescriptions, formula granules, and replacement of rare and precious medicinal materials. Jinbei Oral Liquid was approved as a preparation for medical institutions in Shandong Province in January 2020 and used for the treatment of new crown patients across the province. It is expected to become an innovative Chinese medicine for the treatment of pulmonary fibrosis. The artificial replacement project of Chansu is expected to fill the gap in new Chinese patent medicines. Hongjitang Pharmaceuticals is a designated enterprise for the production of lung clearing and detoxifying agents approved by the Shandong Provincial Health Commission, the Provincial Administration of Traditional Chinese Medicine and the Provincial Drug Administration. As the first batch of enterprises in Shandong Province's traditional Chinese medicine formula granules research, the first phase of the 3,000-ton formula granules project has been put into production. According to the path from the provincial standard to the national standard, it will lead the research on formula granules standards in Shandong Province. After all, 600 varieties will be realized. Production.
Shandong Hongjitang Pharmaceutical Group Co., Ltd.
The world's traditional Chinese medicine, the century-old Hongjitang. Shandong Hongjitang Pharmaceutical Group Co., Ltd. was founded in 1907 and has a history of more than 110 years. On the basis of inheriting the essence and adhering to the truth and innovation, it has established a modern Hongjitang Traditional Chinese Medicine Health City from a high starting point, completing the traditional manufacturing type to The leap of technology-leading has formed core competitiveness in many aspects. Hongjitang Pharmaceutical currently has 151 documents, and its products cover Chinese patent medicines, formula granules, Chinese herbal medicines, raw materials, donkey-hide gelatin and healthy foods. 35 products have entered the national basic medicine catalog and 90 products have entered the medical insurance catalog. There are 10 large dosage forms (pills, powders, tablets, mixtures, tinctures, gels, capsules, granules, decoctions, oral liquids), and 10 exclusive products (Qianlixin Capsules, Musk Heartburnin Tablets, Jinming Tablets , Compound Xiling Jiedu Capsules, Deer Bone Gum, Hailong Gecko Oral Liquid, Zhaqi Wan, Shuqi Wan, Jiawei Xiangsha Zhishu Wan, Musk Ketone). 10 products are listed as recommended medications for the diagnosis and treatment of new pneumonia (Huoxiang Zhengqi Water, Fangfeng Tongsheng Pills, Angong Niuhuang Pills, Suhexiang Pills, Comfang Xiling Jiedu Capsules/Pills, Lung Clearing and Detoxification Compound, Jinbei Oral Liquid, Qingwen Jiedu Pills, Qipi Pills). In terms of business model and network channels, Hongjitang OTC Pharmaceuticals directly supplies chain pharmacies, adopts the front-store and back-factory model to establish cooperation with more than 80% of the top 100 pharmaceutical chains in the country, and has cooperated with more than 100,000 pharmacies. Through cooperation with nationally renowned commercial companies such as China Resources, Jiuzhoutong, and Sinopharm Holdings, medical products have formed a sales network covering national-level hospitals and primary medical and health service centers, such as Qianlixin Capsules, Musk Heartburnin Tablets, Xuefu Zhuyu Oral Liquid, etc. The clinical efficacy of high-quality products is highly recognized by experts. Supermarket e-commerce channels directly sell the healthy food series to large domestic chain drug retailers, supermarkets, traditional Chinese medicine clinics and other terminals, and provide customers with products through online platforms such as JD.com and Tmall. Hongjitang Pharmaceutical has enhanced its core competitiveness through innovation, and has more than 10 scientific research and innovation platforms, including Shandong Traditional Chinese Medicine Technology Innovation Center for the Treatment of Respiratory Diseases, Traditional Chinese Medicine Development Strategy Research Center, Shandong Postdoctoral Innovation Practice Base, etc., and undertakes the country and province. Research on many major projects at the level. We cooperate closely with many academicians, national medical masters, and well-known scientific research institutes to hire many famous old Chinese medicine doctors to serve as honorary deans of the institute. On the one hand, we will carry out dosage form improvement, process improvement, clinical re-evaluation and other second rounds around the existing 151 document numbers. Development and research; on the other hand, focus on the advantages of traditional Chinese medicine, and carry out research in the directions of new traditional Chinese medicine, classic prescriptions, formula granules, and replacement of rare and precious medicinal materials. Jinbei Oral Liquid was approved as a preparation for medical institutions in Shandong Province in January 2020 and used for the treatment of new crown patients across the province. It is expected to become an innovative Chinese medicine for the treatment of pulmonary fibrosis. The artificial replacement project of Chansu is expected to fill the gap in new Chinese patent medicines. Hongjitang Pharmaceuticals is a designated enterprise for the production of lung clearing and detoxifying agents approved by the Shandong Provincial Health Commission, the Provincial Administration of Traditional Chinese Medicine and the Provincial Drug Administration. As the first batch of enterprises in Shandong Province's traditional Chinese medicine formula granules research, the first phase of the 3,000-ton formula granules project has been put into production. According to the path from the provincial standard to the national standard, it will lead the research on formula granules standards in Shandong Province. After all, 600 varieties will be realized. Production.
Harbin Pharmaceutical Group Co., Ltd.
Harbin Pharmaceutical Group Co., Ltd. ( hereinafter referred to as "Habin Pharmaceutical Co., Ltd." ) is a large enterprise group integrating pharmaceutical manufacturing, trade and scientific research. In June 1993, the company was listed on the Shanghai Stock Exchange (stock code "600664"). The company covers three core business segments of industrial manufacturing, commerce and GNC. It has 10 industrial enterprises including Harbin Pharmaceutical Sanjing, Harbin Pharmaceutical General Factory, Harbin Pharmaceutical Six Factory, and Harbin Pharmaceutical Shiyitang. Harbin Pharmaceutical Renmin Tongtai (listed company ) and Harbin Pharmaceutical Marketing two commercial distribution companies, and also has a pharmaceutical research institute with strong scientific research capabilities, focusing on innovative research and development in high-tech fields such as central nervous system, anti-tumor, cardiovascular and cerebrovascular drugs. Hayao Co., Ltd. has 1,816 drug approvals and 74 health food approvals. The leading products include calcium gluconate oral solution, zinc gluconate oral solution, amoxicillin capsules, Shuanghuanglian oral solution, prostadil injection, and pediatric aminophen yellow. Namin granules, Rasidipin tablets, ceftiam hydrochloride for injection, ibuprofen granules, Xingai Zhonggai brand high calcium tablets, etc. The company owns five trademarks: "Haya Medicine", "Three Essences", "Guizhong Gai", "Hutong" and "Shiyitang", with a brand value of more than 20 billion yuan. Integrity, professionalism, openness and inclusiveness, collaboration and responsibility, innovation and efficiency are the core values of corporate development. Harbin Pharmaceutical Co., Ltd. is an enterprise with relatively innovative capabilities and pioneering spirit. In the future, the company will coordinate the talent chain, industrial chain and capital chain, comprehensively build an open innovation ecosystem, constantly explore high-quality development paths, and continue to make efforts in many fields such as products, technology, R&D, intelligent manufacturing, business models, and management mechanisms. Breakthrough and transformation make Harbin Pharmaceutical a benchmark for Chinese national pharmaceutical companies that consumers, customers, employees and society are proud of.
Harbin Pharmaceutical Group Co., Ltd.
Harbin Pharmaceutical Group Co., Ltd. ( hereinafter referred to as "Habin Pharmaceutical Co., Ltd." ) is a large enterprise group integrating pharmaceutical manufacturing, trade and scientific research. In June 1993, the company was listed on the Shanghai Stock Exchange (stock code "600664"). The company covers three core business segments of industrial manufacturing, commerce and GNC. It has 10 industrial enterprises including Harbin Pharmaceutical Sanjing, Harbin Pharmaceutical General Factory, Harbin Pharmaceutical Six Factory, and Harbin Pharmaceutical Shiyitang. Harbin Pharmaceutical Renmin Tongtai (listed company ) and Harbin Pharmaceutical Marketing two commercial distribution companies, and also has a pharmaceutical research institute with strong scientific research capabilities, focusing on innovative research and development in high-tech fields such as central nervous system, anti-tumor, cardiovascular and cerebrovascular drugs. Hayao Co., Ltd. has 1,816 drug approvals and 74 health food approvals. The leading products include calcium gluconate oral solution, zinc gluconate oral solution, amoxicillin capsules, Shuanghuanglian oral solution, prostadil injection, and pediatric aminophen yellow. Namin granules, Rasidipin tablets, ceftiam hydrochloride for injection, ibuprofen granules, Xingai Zhonggai brand high calcium tablets, etc. The company owns five trademarks: "Haya Medicine", "Three Essences", "Guizhong Gai", "Hutong" and "Shiyitang", with a brand value of more than 20 billion yuan. Integrity, professionalism, openness and inclusiveness, collaboration and responsibility, innovation and efficiency are the core values of corporate development. Harbin Pharmaceutical Co., Ltd. is an enterprise with relatively innovative capabilities and pioneering spirit. In the future, the company will coordinate the talent chain, industrial chain and capital chain, comprehensively build an open innovation ecosystem, constantly explore high-quality development paths, and continue to make efforts in many fields such as products, technology, R&D, intelligent manufacturing, business models, and management mechanisms. Breakthrough and transformation make Harbin Pharmaceutical a benchmark for Chinese national pharmaceutical companies that consumers, customers, employees and society are proud of.
Zhuzhou Qianjin Pharmaceutical Co., Ltd.
Qianjin Pharmaceutical was founded in 1966, carried out joint-stock transformation in 1993, and was listed on the Shanghai Stock Exchange in 2004. The group has 10 holding subsidiaries and has employees of about 7,000. The company's business scope covers fields such as Chinese patent medicines, chemical medicines, Chinese medicine derivatives, wholesale and retail of drugs, and planting and processing of Chinese medicinal materials. In 2006, the company's main product, gynecological daughter tablets, was recognized as a "state secret technology variety"; gynecological daughter tablets (capsules) have been a Category A variety of "National Medical Insurance Catalog" since 1998, and were selected for the 2009 edition, 2012 edition, and 2018 edition. "National Basic Drug Catalog"; Buxue Yimu Pills (granules) have been a variety of "National Medical Insurance Catalog" since 2010 and were selected into the 2018 edition of the "National Basic Drug Catalog".
Zhuzhou Qianjin Pharmaceutical Co., Ltd.
Qianjin Pharmaceutical was founded in 1966, carried out joint-stock transformation in 1993, and was listed on the Shanghai Stock Exchange in 2004. The group has 10 holding subsidiaries and has employees of about 7,000. The company's business scope covers fields such as Chinese patent medicines, chemical medicines, Chinese medicine derivatives, wholesale and retail of drugs, and planting and processing of Chinese medicinal materials. In 2006, the company's main product, gynecological daughter tablets, was recognized as a "state secret technology variety"; gynecological daughter tablets (capsules) have been a Category A variety of "National Medical Insurance Catalog" since 1998, and were selected for the 2009 edition, 2012 edition, and 2018 edition. "National Basic Drug Catalog"; Buxue Yimu Pills (granules) have been a variety of "National Medical Insurance Catalog" since 2010 and were selected into the 2018 edition of the "National Basic Drug Catalog".
Beaufour Ipsen Pharma Tianjin Co., Ltd.
Ipsong is committed to improving people's lives and health. Our 5,700 employees around the world work to address unmet disease treatment needs to improve the quality of life for patients and caregivers. Among the world's leading pharmaceutical companies specializing in oncology research, Ipson is conquering cancers that need to be treated urgently. With over 25 years of research, development and business experience in the field of neuroscience, Ipson continues to work to improve the health of patients suffering from debilitating neurological diseases. Ipson is committed to providing innovative treatment options for patients with rare diseases. By focusing on these rare diseases, we have brought about substantial change in certain areas where treatment needs are not met.
Beaufour Ipsen Pharma Tianjin Co., Ltd.
Ipsong is committed to improving people's lives and health. Our 5,700 employees around the world work to address unmet disease treatment needs to improve the quality of life for patients and caregivers. Among the world's leading pharmaceutical companies specializing in oncology research, Ipson is conquering cancers that need to be treated urgently. With over 25 years of research, development and business experience in the field of neuroscience, Ipson continues to work to improve the health of patients suffering from debilitating neurological diseases. Ipson is committed to providing innovative treatment options for patients with rare diseases. By focusing on these rare diseases, we have brought about substantial change in certain areas where treatment needs are not met.
Hunan Warner Pharmaceutical Co., Ltd.
Hunan Warner Pharmaceutical Factory Co., Ltd. was founded in 2001 with a registered capital of 70.3 million yuan. The company adheres to the corporate purpose of "technology and serving health", follows the corporate business philosophy of "concentrating on pharmaceuticals and treating people with integrity", adheres to the professional development path, takes quality as a guarantee and service as a support, and strives to build the company into "a worthwhile one. Trusted supplier of health products”. Hunan Warner Pharmaceutical Factory Co., Ltd. has jointly established two R&D platforms, including the local Central South University, Hunan University of Traditional Chinese Medicine and other institutions, and has expanded the company's future chemical pharmaceutical production. The living space of the field and the fields of traditional Chinese medicine and natural medicine: In the field of chemical drugs, with the product combination of gradual and series as the main line, we continue to carry out slow-release preparations, small-volume injection and lyophilized powder injection products in the field of generic drugs. R&D, improve the R&D capabilities of chemical and generic drugs, and further ensure the company's future sustainable growth capabilities. At the same time, through R&D outsourcing, cooperation, introduction and other methods, we will plan the research and development of original chemical new drugs to promote the transformation and upgrading of corporate innovation. In the field of traditional Chinese medicine, guided by modern Chinese medicine, we will continue to develop the research and development of traditional Chinese medicine granule decoctions, new Chinese medicine drugs, and plant-extraction raw materials. At the same time, we will carry out international registration of plant-extraction raw materials to make the Chinese medicine industry bigger and stronger. Hunan Warner Pharmaceutical Factory Co., Ltd. plans three production bases: Hunan Warner Pharmaceutical Factory (chemical preparation production base, Hunan Liuyang Economic Development Zone), Hunan Warner Pharmaceutical Factory Natural Medicine Co., Ltd. (Traditional medicine production base, Hunan Liuyang Economic and Technological Development Zone The area opened), Hunan Warner Pharmaceutical Factory Chiral Drug Co., Ltd. (chemical raw materials production base, Hunan Wangcheng Tongguan Circular Economy Park), has initially formed a well-equipped combination from chemical raw materials to chemical drug preparations, from traditional Chinese medicine resources to the Chinese medicine resources The complete industrial chain of patent medicines and plant extracts, the specialization, scale and automation level of the production platform continues to improve, and the production costs are effectively reduced, thus creating favorable conditions for the improvement of product market competitiveness and product market share. Hunan Warner Pharmaceutical Co., Ltd. has set up an office in the domestic sub-region to carry out academic promotion of medical institutions in the region and market promotion of OTC terminals, expand the production capacity of the preparation sales team to promote the terminal, and promote the sales scale of single products. To achieve the simultaneous growth of sales personnel and single product scale. Preparation products Dokuester sodium tablets, colloidal bismuth dry suspension, Fosfomycin tereamyl powder, Faropenem sodium granules, diclofenac sodium sustained release tablets, Ginkgo leaf dispersion tablets, naked flower purple bead dispersion tablets, Golden chicken The scale and brand of dispersed tablets, ginseng royal jelly chewable tablets, and raw materials such as colloidal bismuth pectin, pantoprazole sodium, fosfomycin teramol, and faropenem sodium are constantly increasing.
Hunan Warner Pharmaceutical Co., Ltd.
Hunan Warner Pharmaceutical Factory Co., Ltd. was founded in 2001 with a registered capital of 70.3 million yuan. The company adheres to the corporate purpose of "technology and serving health", follows the corporate business philosophy of "concentrating on pharmaceuticals and treating people with integrity", adheres to the professional development path, takes quality as a guarantee and service as a support, and strives to build the company into "a worthwhile one. Trusted supplier of health products”. Hunan Warner Pharmaceutical Factory Co., Ltd. has jointly established two R&D platforms, including the local Central South University, Hunan University of Traditional Chinese Medicine and other institutions, and has expanded the company's future chemical pharmaceutical production. The living space of the field and the fields of traditional Chinese medicine and natural medicine: In the field of chemical drugs, with the product combination of gradual and series as the main line, we continue to carry out slow-release preparations, small-volume injection and lyophilized powder injection products in the field of generic drugs. R&D, improve the R&D capabilities of chemical and generic drugs, and further ensure the company's future sustainable growth capabilities. At the same time, through R&D outsourcing, cooperation, introduction and other methods, we will plan the research and development of original chemical new drugs to promote the transformation and upgrading of corporate innovation. In the field of traditional Chinese medicine, guided by modern Chinese medicine, we will continue to develop the research and development of traditional Chinese medicine granule decoctions, new Chinese medicine drugs, and plant-extraction raw materials. At the same time, we will carry out international registration of plant-extraction raw materials to make the Chinese medicine industry bigger and stronger. Hunan Warner Pharmaceutical Factory Co., Ltd. plans three production bases: Hunan Warner Pharmaceutical Factory (chemical preparation production base, Hunan Liuyang Economic Development Zone), Hunan Warner Pharmaceutical Factory Natural Medicine Co., Ltd. (Traditional medicine production base, Hunan Liuyang Economic and Technological Development Zone The area opened), Hunan Warner Pharmaceutical Factory Chiral Drug Co., Ltd. (chemical raw materials production base, Hunan Wangcheng Tongguan Circular Economy Park), has initially formed a well-equipped combination from chemical raw materials to chemical drug preparations, from traditional Chinese medicine resources to the Chinese medicine resources The complete industrial chain of patent medicines and plant extracts, the specialization, scale and automation level of the production platform continues to improve, and the production costs are effectively reduced, thus creating favorable conditions for the improvement of product market competitiveness and product market share. Hunan Warner Pharmaceutical Co., Ltd. has set up an office in the domestic sub-region to carry out academic promotion of medical institutions in the region and market promotion of OTC terminals, expand the production capacity of the preparation sales team to promote the terminal, and promote the sales scale of single products. To achieve the simultaneous growth of sales personnel and single product scale. Preparation products Dokuester sodium tablets, colloidal bismuth dry suspension, Fosfomycin tereamyl powder, Faropenem sodium granules, diclofenac sodium sustained release tablets, Ginkgo leaf dispersion tablets, naked flower purple bead dispersion tablets, Golden chicken The scale and brand of dispersed tablets, ginseng royal jelly chewable tablets, and raw materials such as colloidal bismuth pectin, pantoprazole sodium, fosfomycin teramol, and faropenem sodium are constantly increasing.
Kangzhi Pharmaceutical Co., Ltd.
Kangzhi Pharmaceutical Co., Ltd. is a listed company focusing on children's health (stock abbreviation: Kangzhi Pharmaceutical, stock code: 300086). The main business covers children's medicine, maternal and infant health products, medical services and other fields. It is a national high-tech enterprise and has established a postdoctoral research station with children's medicine as its main research direction. The company adheres to the corporate purpose of "being sincere and good at doing medicine and benefiting mankind", actively implements the "children's big health strategy" and "quality strategy", and ingeniously creates a national brand of the children's big health industry. Kangzhi Pharmaceutical has been deeply engaged in the children's drug market for many years and has formed a complete product line. It is one of the few pharmaceutical companies in China that have the entire industrial chain of children's drug research and development, production and sales. The company's territory is nationwide, with five major production bases in Hainan, Beijing, Hebei, Liaoning and Guangdong provinces and cities, and highly automated and intelligent production lines. The company has advanced R&D equipment and excellent R&D team. In 2018, Kangzhi Pharmaceutical acquired Zhongshan Aihu Daily necessities Co., Ltd., and its business layout extended to the maternal and infant health sector. Kangzhi Children's Big Health Map is becoming more and more perfect. Aihu Company has successively established cooperation with many domestic and foreign scientific research institutions and universities, and has been invited to participate in the formulation of the "Liquid Detergent for Infant and Children's Clothing Materials" standards. It is a benchmark enterprise in the field of maternal and infant health in China. At the beginning of 2020, the new crown pneumonia epidemic swept the world. Kangzhi Pharmaceutical was ordered to volunteer to produce masks and other protective materials in an emergency. It built Hainan's first disposable medical mask production line in just 8 days, and successfully obtained ENISO13485:2016 EU Quality Management System Certification , and in September 2020, he became a manufacturer of anti-epidemic mask materials for the United Nations Development Program.
Kangzhi Pharmaceutical Co., Ltd.
Kangzhi Pharmaceutical Co., Ltd. is a listed company focusing on children's health (stock abbreviation: Kangzhi Pharmaceutical, stock code: 300086). The main business covers children's medicine, maternal and infant health products, medical services and other fields. It is a national high-tech enterprise and has established a postdoctoral research station with children's medicine as its main research direction. The company adheres to the corporate purpose of "being sincere and good at doing medicine and benefiting mankind", actively implements the "children's big health strategy" and "quality strategy", and ingeniously creates a national brand of the children's big health industry. Kangzhi Pharmaceutical has been deeply engaged in the children's drug market for many years and has formed a complete product line. It is one of the few pharmaceutical companies in China that have the entire industrial chain of children's drug research and development, production and sales. The company's territory is nationwide, with five major production bases in Hainan, Beijing, Hebei, Liaoning and Guangdong provinces and cities, and highly automated and intelligent production lines. The company has advanced R&D equipment and excellent R&D team. In 2018, Kangzhi Pharmaceutical acquired Zhongshan Aihu Daily necessities Co., Ltd., and its business layout extended to the maternal and infant health sector. Kangzhi Children's Big Health Map is becoming more and more perfect. Aihu Company has successively established cooperation with many domestic and foreign scientific research institutions and universities, and has been invited to participate in the formulation of the "Liquid Detergent for Infant and Children's Clothing Materials" standards. It is a benchmark enterprise in the field of maternal and infant health in China. At the beginning of 2020, the new crown pneumonia epidemic swept the world. Kangzhi Pharmaceutical was ordered to volunteer to produce masks and other protective materials in an emergency. It built Hainan's first disposable medical mask production line in just 8 days, and successfully obtained ENISO13485:2016 EU Quality Management System Certification , and in September 2020, he became a manufacturer of anti-epidemic mask materials for the United Nations Development Program.
Yangtze River Pharmaceutical Group Co., Ltd.
Founded in 1971, Yangtze River Pharmaceutical Group is a large national pharmaceutical enterprise group and an early innovative enterprise named by the Ministry of Science and Technology. The group is headquartered in Taizhou City, Jiangsu Province, with more than 16,000 employees. More than 20 member companies are located in Taizhou, Beijing, Shanghai, Nanjing, Guangzhou, Chengdu, Suzhou, Changzhou and other places; the marketing network covers all provinces and cities across the country except Taiwan. ,autonomous region. The group practices the core values of "high-quality benefiting the people and innovation and goodness" and focuses on providing high-quality medicines and health services to the society. The Group implements the development policy of "quality first and efficiency first" and has multiple innovative R&D platforms. The Yangtze River water nurtures China, and the Yangtze River medicine benefits China. Under the guidance of the spirit of the 19th National Congress of the Communist Party of China, Yangtze River Pharmaceutical has continued to deepen supply-side structural reform, implemented the big health industry strategy, kept its original aspiration in mind, kept its mission in mind, forged ahead, and strived to achieve the 13th Five-Year Plan sales target of 100 billion yuan. Aspire to become a world-renowned pharmaceutical company in the field of health.
Yangtze River Pharmaceutical Group Co., Ltd.
Founded in 1971, Yangtze River Pharmaceutical Group is a large national pharmaceutical enterprise group and an early innovative enterprise named by the Ministry of Science and Technology. The group is headquartered in Taizhou City, Jiangsu Province, with more than 16,000 employees. More than 20 member companies are located in Taizhou, Beijing, Shanghai, Nanjing, Guangzhou, Chengdu, Suzhou, Changzhou and other places; the marketing network covers all provinces and cities across the country except Taiwan. ,autonomous region. The group practices the core values of "high-quality benefiting the people and innovation and goodness" and focuses on providing high-quality medicines and health services to the society. The Group implements the development policy of "quality first and efficiency first" and has multiple innovative R&D platforms. The Yangtze River water nurtures China, and the Yangtze River medicine benefits China. Under the guidance of the spirit of the 19th National Congress of the Communist Party of China, Yangtze River Pharmaceutical has continued to deepen supply-side structural reform, implemented the big health industry strategy, kept its original aspiration in mind, kept its mission in mind, forged ahead, and strived to achieve the 13th Five-Year Plan sales target of 100 billion yuan. Aspire to become a world-renowned pharmaceutical company in the field of health.
Hunan FangSheng Pharmaceutical Co., Ltd.
Founded in June 2002, Fangsheng Pharmaceutical is a high-quality, comprehensive, scientific research-based pharmaceutical and health industry group integrating pharmaceutical industry, medical services and big health businesses. It has many subsidiaries, December 5, 2014. It was successfully listed on the Shanghai Stock Exchange on the day and officially entered the capital market (stock code: 603998). From the establishment of the factory to the present, Fang Sheng has risen rapidly with a steady development speed and has grown into a benchmark enterprise in the pharmaceutical industry in Hunan Province. Fang Sheng takes "Your health, Fang Sheng's pursuit" as the corporate mission. Over the past 10 years, it has been constantly exploring, trying and developing in all fields of big health, always committed to serving human health, and building a pharmaceutical industry as the The main body, with medical services and big health (health consumption, elderly care) as the strategic layout of "one body and two wings". In the pharmaceutical industry, Fangsheng Pharmaceutical Headquarters is the main body, and its subsidiary Xiangya Pharmaceuticals, Hainan Boda, Sanhua Pharmaceuticals, etc. are assisted in the joint development; at the same time, it will quickly promote the construction of Fangsheng Lip's international factory to create a way that can meet both the FDA and the NMPA. International technology platform to accelerate integration with the international market; in terms of the medical industry, relying on the two industrial funds investment targets of Baijun Medical and Kexin Health, the company's participation in investment, to meet the people's growing growth in the two major areas of kidney disease and tumors. Health service needs; in terms of healthy elderly care, using Xiangya Pharmaceutical's "Xiangya Xileyuan" as a carrier to create an elderly care life model that combines "nursing homes" and "rizhao centers" to promote the company's development layout in the elderly care industry. Fang Sheng takes "new drug research and development capabilities" as the company's core competitive advantage, integrates the advantages of global new drug research and development resources, forms a high-level R&D team, and establishes three drugs, "Traditional medicine, chemical medicine, and biological medicine", using the imitation of complex chemical preparations, Improvement and innovation and product R&D strategies with internationalization as important characteristics have been continuously promoted to the "1+N" model of internationalized large-scale R&D system, achieving integrated development in multiple technologies and fields. In the field of traditional Chinese medicine, Fang Sheng has successfully developed several major brand series products such as Xinxuean brand cardiovascular and cerebrovascular department, Jinbeibei brand pediatrics, Meiershu brand gynecology, and Fangshengtang brand orthopedic department. In the field of chemical drugs, Fang Sheng is committed to focusing on the development of blockbuster drugs for the prevention and treatment of major diseases. The first phase I clinical trial of Deantecon sodium for injection of the Class 1 anti-cancer drug independently developed by its subsidiary Fang Sheng Huamei is about to be completed. The Phase I clinical trial of Lipo in the United States is about to be completed. Paclitaxel for injection (albumin-binding type) has completed the preliminary research and development work. In the field of biopharmaceuticals, the "National Engineering Research Center for Genetic Engineering Drugs" of Jida Genetics has successfully passed the acceptance, and its future development prospects are broad. At present, Fang Sheng has achieved the management of the entire value chain of pharmaceutical research, clinical research, consistency evaluation, production and sales in the field of new drug research and development. The company now has a nationally certified enterprise technology center and a postdoctoral research workstation. It undertakes major national new drug creation science and technology projects and a number of provincial and ministerial science and technology projects. It has obtained more than 160 drug production approval documents, nearly 20 new drug certificates, and nearly 40 invention patents. , 2 international patents, rich product reserves, provide strong support for realizing Fangsheng strategy and meeting people's health needs. Fang Sheng has formed a professional marketing team, and the marketing network covers hospitals, chains, single pharmacies and clinics at all levels in provinces and cities across the country. With excellent product quality and professional and high-quality services, it has established the Fang Sheng brand in the field of medicine. The company fully promotes professional and academic marketing, and through diversified academic activities, we work with medical institutions at all levels to jointly improve China's overall medical level. Fang Sheng has multiple production bases in Changsha, Hainan, Liaoning, Yunnan and other places. He organizes production strictly in accordance with the requirements of the new version of GMP and excellent performance system, establishes a complete quality control and assurance system, and implements the quality management of the entire process and all employees. Ensure the quality and safety of people's medication use. Among them, Fangsheng Pharmaceutical Industrial Park, located in Changsha Hi-tech Zone, covers an area of 150 mu and has a total construction area of 230,000 square meters, providing strong support for the company's production capacity required in its strategic development. In the future, Fangsheng will continue to take the pharmaceutical industry as the main body, strengthen the core competitive advantages of new drug research and development, and leverage the power of capital to leverage the development of the industry, and ultimately realize the "one body and two wings" strategic layout of the pharmaceutical industry, medical services, and healthy elderly care, and create high-quality, Comprehensive and scientific research-based pharmaceutical and health industry aircraft carriers realize Fang Sheng’s dream and achieve the dream of health!
Hunan FangSheng Pharmaceutical Co., Ltd.
Founded in June 2002, Fangsheng Pharmaceutical is a high-quality, comprehensive, scientific research-based pharmaceutical and health industry group integrating pharmaceutical industry, medical services and big health businesses. It has many subsidiaries, December 5, 2014. It was successfully listed on the Shanghai Stock Exchange on the day and officially entered the capital market (stock code: 603998). From the establishment of the factory to the present, Fang Sheng has risen rapidly with a steady development speed and has grown into a benchmark enterprise in the pharmaceutical industry in Hunan Province. Fang Sheng takes "Your health, Fang Sheng's pursuit" as the corporate mission. Over the past 10 years, it has been constantly exploring, trying and developing in all fields of big health, always committed to serving human health, and building a pharmaceutical industry as the The main body, with medical services and big health (health consumption, elderly care) as the strategic layout of "one body and two wings". In the pharmaceutical industry, Fangsheng Pharmaceutical Headquarters is the main body, and its subsidiary Xiangya Pharmaceuticals, Hainan Boda, Sanhua Pharmaceuticals, etc. are assisted in the joint development; at the same time, it will quickly promote the construction of Fangsheng Lip's international factory to create a way that can meet both the FDA and the NMPA. International technology platform to accelerate integration with the international market; in terms of the medical industry, relying on the two industrial funds investment targets of Baijun Medical and Kexin Health, the company's participation in investment, to meet the people's growing growth in the two major areas of kidney disease and tumors. Health service needs; in terms of healthy elderly care, using Xiangya Pharmaceutical's "Xiangya Xileyuan" as a carrier to create an elderly care life model that combines "nursing homes" and "rizhao centers" to promote the company's development layout in the elderly care industry. Fang Sheng takes "new drug research and development capabilities" as the company's core competitive advantage, integrates the advantages of global new drug research and development resources, forms a high-level R&D team, and establishes three drugs, "Traditional medicine, chemical medicine, and biological medicine", using the imitation of complex chemical preparations, Improvement and innovation and product R&D strategies with internationalization as important characteristics have been continuously promoted to the "1+N" model of internationalized large-scale R&D system, achieving integrated development in multiple technologies and fields. In the field of traditional Chinese medicine, Fang Sheng has successfully developed several major brand series products such as Xinxuean brand cardiovascular and cerebrovascular department, Jinbeibei brand pediatrics, Meiershu brand gynecology, and Fangshengtang brand orthopedic department. In the field of chemical drugs, Fang Sheng is committed to focusing on the development of blockbuster drugs for the prevention and treatment of major diseases. The first phase I clinical trial of Deantecon sodium for injection of the Class 1 anti-cancer drug independently developed by its subsidiary Fang Sheng Huamei is about to be completed. The Phase I clinical trial of Lipo in the United States is about to be completed. Paclitaxel for injection (albumin-binding type) has completed the preliminary research and development work. In the field of biopharmaceuticals, the "National Engineering Research Center for Genetic Engineering Drugs" of Jida Genetics has successfully passed the acceptance, and its future development prospects are broad. At present, Fang Sheng has achieved the management of the entire value chain of pharmaceutical research, clinical research, consistency evaluation, production and sales in the field of new drug research and development. The company now has a nationally certified enterprise technology center and a postdoctoral research workstation. It undertakes major national new drug creation science and technology projects and a number of provincial and ministerial science and technology projects. It has obtained more than 160 drug production approval documents, nearly 20 new drug certificates, and nearly 40 invention patents. , 2 international patents, rich product reserves, provide strong support for realizing Fangsheng strategy and meeting people's health needs. Fang Sheng has formed a professional marketing team, and the marketing network covers hospitals, chains, single pharmacies and clinics at all levels in provinces and cities across the country. With excellent product quality and professional and high-quality services, it has established the Fang Sheng brand in the field of medicine. The company fully promotes professional and academic marketing, and through diversified academic activities, we work with medical institutions at all levels to jointly improve China's overall medical level. Fang Sheng has multiple production bases in Changsha, Hainan, Liaoning, Yunnan and other places. He organizes production strictly in accordance with the requirements of the new version of GMP and excellent performance system, establishes a complete quality control and assurance system, and implements the quality management of the entire process and all employees. Ensure the quality and safety of people's medication use. Among them, Fangsheng Pharmaceutical Industrial Park, located in Changsha Hi-tech Zone, covers an area of 150 mu and has a total construction area of 230,000 square meters, providing strong support for the company's production capacity required in its strategic development. In the future, Fangsheng will continue to take the pharmaceutical industry as the main body, strengthen the core competitive advantages of new drug research and development, and leverage the power of capital to leverage the development of the industry, and ultimately realize the "one body and two wings" strategic layout of the pharmaceutical industry, medical services, and healthy elderly care, and create high-quality, Comprehensive and scientific research-based pharmaceutical and health industry aircraft carriers realize Fang Sheng’s dream and achieve the dream of health!
Simcere Pharmaceutical Group Ltd.
Xiansheng Pharmaceutical (2096.HK) is an innovation and R&D-driven pharmaceutical company with the "National Key Laboratory of Neurological and Oncology Drug R&D". The company focuses on the fields of tumors, nervous system, autoimmune and anti-infection, and is also actively and proactively planning for the fields of diseases with major clinical needs in the future, and is committed to allowing patients to use more effective drugs as soon as possible. The company has established strategic partnerships with many innovative enterprises and research institutions through the dual-wheel drive of independent research and development and collaborative innovation.
Simcere Pharmaceutical Group Ltd.
Xiansheng Pharmaceutical (2096.HK) is an innovation and R&D-driven pharmaceutical company with the "National Key Laboratory of Neurological and Oncology Drug R&D". The company focuses on the fields of tumors, nervous system, autoimmune and anti-infection, and is also actively and proactively planning for the fields of diseases with major clinical needs in the future, and is committed to allowing patients to use more effective drugs as soon as possible. The company has established strategic partnerships with many innovative enterprises and research institutions through the dual-wheel drive of independent research and development and collaborative innovation.
Shanxi Qianyuan Pharmaceutical Group Co., Ltd.
Shanxi Qianyuan Pharmaceutical Group Co., Ltd. is a pharmaceutical listed group enterprise integrating R&D, production and marketing. The company's predecessor, Shanxi Qianyuan Pharmaceutical Co., Ltd., was established on March 23, 2005. It has developed from a small pharmaceutical company with only more than 100 employees and two main products to this day. The group currently has more than 1,600 employees and provides products and services. There are 34 provincial administrative regions across the country and gradually extend their business to international markets and precision medicine fields. The company changed its name to Shanxi Qianyuan Pharmaceutical Co., Ltd. in June 2010 and was successfully listed on the Shenzhen Stock Exchange GEM on August 19, 2011. In September 2014, the company was renamed Shanxi Qianyuan Pharmaceutical Group Co., Ltd., with the securities abbreviation "Qianyuan Pharmaceutical" (stock code: 300254). During the development process, Qianyuan Pharmaceutical has relied on its keen market sense and strategic vision to continuously use external mergers and acquisitions and investments to help enterprises quickly seize market opportunities, optimize product structure, and achieve leapfrog development. Up to now, the group owns 10 wholly-owned and holding subsidiaries including Hangzhou Baoling Pharmaceutical, Zhejiang Hailisheng Pharmaceutical, Jiangsu Jiayi Pharmaceutical, Hangzhou Enshi Gene, Sichuan Qianyuan Traditional Chinese Medicine, Wuxi United Likang Inspection and Tibet Qianyuan. , the group headquarters and marketing department are located in Shanghai. Qianyuan Pharmaceutical has a modern production base, distribution center and a high-level R&D team, in many fields such as chemical synthetic drugs, biological drugs, natural drugs, raw material intermediates, Chinese patent medicines, Chinese herbal medicines, nutritional health products, and pharmaceutical circulation. It has a strong industrial foundation and is committed to building a large pharmaceutical and health industry group with the entire industrial chain of the pharmaceutical industry.
Shanxi Qianyuan Pharmaceutical Group Co., Ltd.
Shanxi Qianyuan Pharmaceutical Group Co., Ltd. is a pharmaceutical listed group enterprise integrating R&D, production and marketing. The company's predecessor, Shanxi Qianyuan Pharmaceutical Co., Ltd., was established on March 23, 2005. It has developed from a small pharmaceutical company with only more than 100 employees and two main products to this day. The group currently has more than 1,600 employees and provides products and services. There are 34 provincial administrative regions across the country and gradually extend their business to international markets and precision medicine fields. The company changed its name to Shanxi Qianyuan Pharmaceutical Co., Ltd. in June 2010 and was successfully listed on the Shenzhen Stock Exchange GEM on August 19, 2011. In September 2014, the company was renamed Shanxi Qianyuan Pharmaceutical Group Co., Ltd., with the securities abbreviation "Qianyuan Pharmaceutical" (stock code: 300254). During the development process, Qianyuan Pharmaceutical has relied on its keen market sense and strategic vision to continuously use external mergers and acquisitions and investments to help enterprises quickly seize market opportunities, optimize product structure, and achieve leapfrog development. Up to now, the group owns 10 wholly-owned and holding subsidiaries including Hangzhou Baoling Pharmaceutical, Zhejiang Hailisheng Pharmaceutical, Jiangsu Jiayi Pharmaceutical, Hangzhou Enshi Gene, Sichuan Qianyuan Traditional Chinese Medicine, Wuxi United Likang Inspection and Tibet Qianyuan. , the group headquarters and marketing department are located in Shanghai. Qianyuan Pharmaceutical has a modern production base, distribution center and a high-level R&D team, in many fields such as chemical synthetic drugs, biological drugs, natural drugs, raw material intermediates, Chinese patent medicines, Chinese herbal medicines, nutritional health products, and pharmaceutical circulation. It has a strong industrial foundation and is committed to building a large pharmaceutical and health industry group with the entire industrial chain of the pharmaceutical industry.
Tibet Yiming Sia Pharmaceutical Technology Co., Ltd.
Tibet Yiming Xiya Pharmaceutical Technology Co., Ltd. (hereinafter referred to as Yiming Pharmaceutical) was established in December 2003. It is a comprehensive pharmaceutical enterprise integrating R&D, production and sales. The company is headquartered in the National Economic and Technological Development Zone of Lhasa City, Tibet Autonomous Region, and owns Beijing Yiming Kangyuan Pharmaceutical Technology Co., Ltd., Chengdu Yiming Kangyuan Pharmaceutical Technology Co., Ltd., Lhasa Yiming Kangyuan Pharmaceutical Technology Co., Ltd., and Beijing Yiming Haizhong Investment Management Co., Ltd. and Sichuan Viao Pharmaceutical Co., Ltd. The planting base is located in Linzhi, Tibet, the production base is located in Lhasa and Pengzhou, Sichuan, and the marketing network is spread all over the country. The company has always been committed to the treatment of chronic diseases such as diabetes and cardiovascular diseases and the development and research of core products in the field of gynecological obstetrics. The company's core products Yiming® Aotianpin® Miglitol Tablets and Xintong® Trichosanthes skin injection Liquid, Yimefen® Namefen Hydrochloride Injection, Yiming® Xinnuoshu® Carbecoxon Injection, Yiming® Meixiaodan® Red Gold Xiaojie Tablets, Weipufen® Aceclofenac Intestine All dissolved tablets have been included in the national medical insurance catalog. General medicine products are widely involved in antibiotics, anti-allergics, and digestive systems. The company has always adhered to the corporate philosophy of "simple, pragmatic, innovative and win-win", is simple and practical; adheres to the business philosophy of R&D-driven and result-oriented, and now has invention patents including many domestic first drug patents and award-winning patents. , new drug certificate and drug production registration approval document. The enterprises have successively obtained "Tibet Autonomous Region Science and Technology Small and Medium Enterprises", "National High-tech Enterprises", "National Science and Technology Incubation Enterprises", "Tibet National Science and Technology Incubation Enterprises", and "China Cardiovascular and Cerebrovascular Disease Diagnosis and Treatment Industry Technology Innovation Strategic Alliance ( Tibet)”, “China Patent Excellence Award” and other honors. In recent years, Yiming Pharmaceutical has developed rapidly due to Tibet's unique biological resources advantages and national policy advantages. It was officially listed on the Shenzhen Stock Exchange on December 9, 2016. In the future, the company will continue to utilize its core product advantages, analyze and grasp the challenges and opportunities faced by the market from multiple aspects, adapt to the country's new medical system reform and development model, and systematically build a high-quality human resources management system, financial management system, and operation and development system. . Taking entry into the capital market as a new opportunity, taking "helping patients overcome diseases and always safeguarding people's health" as the corporate vision, and taking high-quality, high-priced and significant clinical value drugs as the soul, shouldering the social responsibilities that Chinese pharmaceutical companies should have , pursue excellence and strive to become a forefront of China's chronic disease field.
Tibet Yiming Sia Pharmaceutical Technology Co., Ltd.
Tibet Yiming Xiya Pharmaceutical Technology Co., Ltd. (hereinafter referred to as Yiming Pharmaceutical) was established in December 2003. It is a comprehensive pharmaceutical enterprise integrating R&D, production and sales. The company is headquartered in the National Economic and Technological Development Zone of Lhasa City, Tibet Autonomous Region, and owns Beijing Yiming Kangyuan Pharmaceutical Technology Co., Ltd., Chengdu Yiming Kangyuan Pharmaceutical Technology Co., Ltd., Lhasa Yiming Kangyuan Pharmaceutical Technology Co., Ltd., and Beijing Yiming Haizhong Investment Management Co., Ltd. and Sichuan Viao Pharmaceutical Co., Ltd. The planting base is located in Linzhi, Tibet, the production base is located in Lhasa and Pengzhou, Sichuan, and the marketing network is spread all over the country. The company has always been committed to the treatment of chronic diseases such as diabetes and cardiovascular diseases and the development and research of core products in the field of gynecological obstetrics. The company's core products Yiming® Aotianpin® Miglitol Tablets and Xintong® Trichosanthes skin injection Liquid, Yimefen® Namefen Hydrochloride Injection, Yiming® Xinnuoshu® Carbecoxon Injection, Yiming® Meixiaodan® Red Gold Xiaojie Tablets, Weipufen® Aceclofenac Intestine All dissolved tablets have been included in the national medical insurance catalog. General medicine products are widely involved in antibiotics, anti-allergics, and digestive systems. The company has always adhered to the corporate philosophy of "simple, pragmatic, innovative and win-win", is simple and practical; adheres to the business philosophy of R&D-driven and result-oriented, and now has invention patents including many domestic first drug patents and award-winning patents. , new drug certificate and drug production registration approval document. The enterprises have successively obtained "Tibet Autonomous Region Science and Technology Small and Medium Enterprises", "National High-tech Enterprises", "National Science and Technology Incubation Enterprises", "Tibet National Science and Technology Incubation Enterprises", and "China Cardiovascular and Cerebrovascular Disease Diagnosis and Treatment Industry Technology Innovation Strategic Alliance ( Tibet)”, “China Patent Excellence Award” and other honors. In recent years, Yiming Pharmaceutical has developed rapidly due to Tibet's unique biological resources advantages and national policy advantages. It was officially listed on the Shenzhen Stock Exchange on December 9, 2016. In the future, the company will continue to utilize its core product advantages, analyze and grasp the challenges and opportunities faced by the market from multiple aspects, adapt to the country's new medical system reform and development model, and systematically build a high-quality human resources management system, financial management system, and operation and development system. . Taking entry into the capital market as a new opportunity, taking "helping patients overcome diseases and always safeguarding people's health" as the corporate vision, and taking high-quality, high-priced and significant clinical value drugs as the soul, shouldering the social responsibilities that Chinese pharmaceutical companies should have , pursue excellence and strive to become a forefront of China's chronic disease field.
SmectiteCare is a gentle antidiarrheal medication suitable for all ages, including infants and the elderly.
Johnson & Johnson
SmectiteCare is a gentle antidiarrheal medication suitable for all ages, including infants and the elderly.
Smectal is a trusted antidiarrheal medication containing smectite, used globally for its effectiveness.
Bayer
Smectal is a trusted antidiarrheal medication containing smectite, used globally for its effectiveness.
Smectite Plus combines smectite with probiotics for enhanced gastrointestinal health and diarrhea treatment.
GlaxoSmithKline
Smectite Plus combines smectite with probiotics for enhanced gastrointestinal health and diarrhea treatment.
SmectaGo is a fast-acting antidiarrheal medication containing diosmectite, designed for quick relief.
Pfizer
SmectaGo is a fast-acting antidiarrheal medication containing diosmectite, designed for quick relief.
Smectite is a natural clay-based product used for treating diarrhea and gastrointestinal discomfort.
Novartis
Smectite is a natural clay-based product used for treating diarrhea and gastrointestinal discomfort.
Neosmectin is a popular antidiarrheal medication containing smectite, widely used in various countries.
Abbott
Neosmectin is a popular antidiarrheal medication containing smectite, widely used in various countries.
Diosmectite is a natural clay-based product used for gastrointestinal disorders, particularly diarrhea.
Sanofi
Diosmectite is a natural clay-based product used for gastrointestinal disorders, particularly diarrhea.
SmectiteComplete is a complete solution for diarrhea, combining smectite with essential nutrients for recovery.
Cipla
SmectiteComplete is a complete solution for diarrhea, combining smectite with essential nutrients for recovery.
